Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MART-1 and Anti-gp100 TCR-Engineered Lymphocytes with Peptide Vaccines in Metastatic Melanoma
NCT00923195Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2008
- Primary completion
- Aug 2011
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, gp100:154-162 reactive peripheral blood lymphocytes, gp100:154-162 Peptide, melan-a analog peptide in melanoma, sponsored by National Cancer Institute. Started Dec 2008; status: completed.
02
Drugs
autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytesgp100:154-162 reactive peripheral blood lymphocytesgp100:154-162 Peptidemelan-a analog peptide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00923195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00923195.